Mounting evidence suggests safety and efficacy of psychedelic compounds as potential
novel therapeutics in psychiatry. Ketamine has been approved by the Food and Drug …

Apathy and anhedonia are common syndromes of motivation that are associated with a wide
range of brain disorders and have no established therapies. Research using animal models …

Biomarkers have transformed modern medicine but remain largely elusive in psychiatry,
partly because there is a weak correspondence between diagnostic labels and their …

Objective: Loss of pleasure or interest in activities (ie, anhedonia) is a risk factor for
suicidality, treatment nonresponse, and relapse. Extant treatments that focus on reducing …

The role of robots in society keeps expanding and diversifying, bringing with it a host of
issues surrounding the relationship between robots and humans. This introduction to human …

Anhedonia—the loss of pleasure or lack of reactivity to pleasurable stimuli—remains a
formidable treatment challenge across neuropsychiatric disorders. In major depressive …

Objective: A role for aberrant reward processing in the pathogenesis of depression has long
been proposed. However, no review has yet examined its role in depression by integrating …

Background Childhood maltreatment is the most important preventable cause of
psychopathology accounting for about 45% of the population attributable risk for childhood …

Cortisol, a critical glucocorticoid hormone produced by the adrenal glands, plays a pivotal
role in various physiological processes. Its release is finely orchestrated by the …

We propose that depression can be viewed as an adaptation to conserve energy after the
perceived loss of an investment in a vital resource such as a relationship, group identity, or …